Skip to main content

Annexon, Inc.

corporate_fare Company Profile

Annexon, Inc.

ANNX·NASDAQ·Life Sciences·CIK 0001528115

Annexon, Inc. is a biopharmaceutical company that develops targeted immunotherapies for complement-mediated neuroinflammatory diseases. These diseases affect nearly 10 million people globally. The company focuses on the classical complement pathway, a part of the body's immune system that triggers inflammation. Annexon aims to stop this pathway at its beginning by targeting C1q, its initiating molecule. This approach is intended to offer comprehensive protection against complement-mediated disorders affecting the body, brain, and eye. Using its proprietary platform, Annexon identifies and characterizes the classical complement pathway's role in three therapeutic areas: autoimmune diseases, neurodegeneration, and ophthalmology. The company is developing product candidates designed to block the early classical cascade and all subsequent pathway components and their tissue-damaging effects. The objective is to suppress excessive or abnormal classical complement activity that causes chronic inflammation and tissue damage, potentially slowing or halting disease progression. This is done while preserving the beneficial immune functions of the lectin and alternative complement pathways, which are involved in clearing pathogens and damaged cells. With over a decade of experience in addressing neuroinflammation, Annexon has shown strong target engagement in the body, brain, and eye, and has achieved clinical proof of concept in multiple diseases.

Annexon, Inc. (NASDAQ:ANNX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ANNX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Annexon Outlines Pivotal 2026 with Key Clinical & Regulatory Milestones for Lead Drug Candidates
  • Annexon Files European MAA for GBS Therapy, Anticipates Pivotal Phase 3 Data for Dry AMD in H2 2026

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$206.69M
Diluted EPS
-$1.34
Op. Cash Flow
-$186.36M
Free Cash Flow
-$186.49M
Operating Income
-$216.41M
Cash & Equivalents
$162.05M
Debt / Equity
0.00×
Shares Outstanding
149.36M sh
Source: 10-K · filed 2026-03-30 · accession 0001193125-26-131782
$3.41 +10.00% today
52-week range · as of 2026-11-09 $2.54 – $7.18
Market cap
$591.37M
Volume
4.5M (1.2× avg)
3-mo avg 3.6M
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ANNX - Filings & News (Page 2)

ANNX
Jan 14, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.67
Real-time Price: $3.41 info
Change: -$3.26 (-49%) info
Market Cap: $591.368M info
ANNX
Jan 12, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.40
Real-time Price: $3.41 info
Change: -$1.99 (-37%) info
Market Cap: $591.368M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets